

# 해외 바이오의약품 임상 현황 (2020.03.30~2020.04.05)

한국바이오의약품협회, 2020.4.7.  
출처: ClinicalTrials.gov

## ○ 미국 58건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04281004	Processed Amniotic Fluid (PAF) Drops After Photorefractive Keratectomy (PRK)	Photorefractive Keratectomy	Biological: Amniotic Fluid (AFED) Other: Saline Solution	University of Utah	Phase 1 Phase 2
NCT04266912	Avelumab and M6620 or Nedisertib for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors	Advanced Malignant Solid Neoplasm Metastatic Malignant Solid Neoplasm Unresectable Malignant Solid Neoplasm	Drug: ATR Kinase Inhibitor M6620 Drug: Avelumab Drug: Nedisertib	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Phase 1 Phase 2
NCT04257578	Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma	B-Cell Non-Hodgkin Lymphoma Diffuse Large B-Cell Lymphoma, Not Otherwise Specified High Grade B-Cell Lymphoma Primary Mediastinal (Thymic) Large B-Cell Lymphoma Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma	Drug: Acalabrutinib Biological: Axicabtagene Ciloleuce	University of Washington National Cancer Institute (NCI) AstraZeneca	Phase 1 Phase 2
NCT04207190	Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia	Recurrent Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia	Drug: Gemtuzumab Ozogamicin Other: Quality-of-Life Assessment Other: Questionnaire Administration Drug: Talazoparib Drug: Talazoparib Tosylate	Roswell Park Cancer Institute National Cancer Institute (NCI)	Phase 1 Phase 2
NCT04201821	Fecal Microbial Transplantation for the Treatment of Fecal Incontinence in Women	Fecal Incontinence	Biological: fecal microbial transplantation (FMT)	University of Pennsylvania	Phase 1 Phase 2
NCT04083898	Isatuximab, Bendamustine, and Prednisone in Penta-Refractory Multiple Myeloma	Multiple Myeloma	Biological: Isatuximab Drug: Bendamustine Drug: Prednisone	Washington University School of Medicine Sanofi	Phase 1 Phase 2
NCT03919929	Treating PCOS With Semaglutide vs Active Lifestyle Intervention	PCOS Adolescent Obesity NAFLD	Drug: Semaglutide 3mg and 7mg [Rybelsus] Other: Weight loss diet	University of Colorado, Denver National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 2 Phase 3
NCT03851081	Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia	Allogeneic Hematopoietic Stem Cell Transplantation Recipient Blasts 5 Percent or More of Bone Marrow Nucleated Cells Blasts 5 Percent or More of Peripheral Blood White Cells CD22 Positive Lymphoblasts 20 Percent or More of Bone Marrow Nucleated Cells Lymphoblasts 20 Percent or More of Peripheral Blood White Cells Recurrent B Acute Lymphoblastic Leukemia Refractory B Acute Lymphoblastic Leukemia	Biological: Inotuzumab Ozogamicin Other: Quality-of-Life Assessment Drug: Vincristine Sulfate Liposome	Roswell Park Cancer Institute National Cancer Institute (NCI) Pfizer	Phase 1 Phase 2
NCT04332874	A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg	Sarcoma Myxofibrosarcoma Undifferentiated Pleomorphic Sarcoma Alveolar Soft Part Sarcoma	Procedure: Isolated Limb Infusion Drug: Pembrolizumab Drug: infusion of melphalan and dactinomycin	Memorial Sloan Kettering Cancer Center	Phase 2
NCT04331795	Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis	COVID-19	Drug: Tocilizumab	University of Chicago	Phase 2
NCT04329325	Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Acute Lymphoblastic Leukemia Philadelphia Chromosome-Positive	Drug: Blinatumomab Procedure: Bone marrow aspiration and biopsy (BMA) Drug: corticosteroids	Memorial Sloan Kettering Cancer Center Amgen	Phase 2
NCT04325672	Convalescent Plasma to Limit Coronavirus Associated Complications	Coronavirus	Biological: Convalescent Plasma	Mayo Clinic	Phase 2
NCT04322643	Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma	Urothelial Carcinoma	Drug: Pembrolizumab Drug: Atezolizumab Drug: Durvalumab Drug: Nivolumab Drug: Avelumab	Case Comprehensive Cancer Center	Phase 2
NCT04318678	CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)	Acute Myeloid Leukemia	Drug: CD123-CAR T Drug: Cyclophosphamide Drug: Fludarabine Drug: Mesna Drug: Rituximab	St. Jude Children's Research Hospital	Phase 1
NCT04317534	Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm	NSCLC, Stage I	Drug: Pembrolizumab	Greg Durm, MD Merck Sharp & Dohme Corp. Big Ten Cancer Research Consortium	Phase 2
NCT04310423	An Inflammatory Challenge Using Endotoxin	Alcohol Use Disorder Inflammatory Response Craving Depressed Mood	Drug: Placebo Biological: Endotoxin	University of California, Los Angeles	Phase 2

## 해외 바이오의약품 임상 현황 (2020.03.30~2020.04.05)

한국바이오의약품협회, 2020.4.7.  
출처: ClinicalTrials.gov

NCT04306367	Study of Pembrolizumab and Olaparib in Bile Duct Cancer	Cholangiocarcinoma	Drug: Pembrolizumab Drug: Olaparib	Georgetown University	Phase 2
NCT04296890	A Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression	Epithelial Ovarian Cancer Peritoneal Cancer Fallopian Tube Cancer	Drug: Mirvetuximab Soravtansine	ImmunoGen, Inc.   IQVIA Biotech	Phase 3
NCT04253964	Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy	Non-small Cell Lung Cancer Performance Status	Drug: Pembrolizumab Drug: Carboplatin Drug: Paclitaxel Drug: Nab paclitaxel Other: Quality of Life Questionnaire, lung cancer-specific (QLQ-LC13) Other: QLQ-C30 Global Health/Quality of Life Questionnaire Other: COPD Assessment Test and modified Medical Research Council Dyspnea Patient Reported Outcomes Drug: Pemetrexed	Wake Forest University Health Sciences National Cancer Institute (NCI)	Phase 2
NCT04248569	DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma	Fibrolamellar Hepatocellular Carcinoma (FLC)	Drug: DNAJB1-PRKACA peptide vaccine Drug: Nivolumab Drug: Ipilimumab	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bristol-Myers Squibb	Phase 1
NCT04219163	Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen	Acute Myeloid Leukemia	Biological: CLL-1.CAR T cells	Baylor College of Medicine The Methodist Hospital System Center for Cell and Gene Therapy, Baylor College of Medicine	Phase 1
NCT04205838	Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma	Diffuse Large B-Cell Lymphoma, Not Otherwise Specified High Grade B-Cell Lymphoma Progressive Disease Recurrent Diffuse Large B-Cell Lymphoma Recurrent High Grade B-Cell Lymphoma Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma Refractory Diffuse Large B-Cell Lymphoma Refractory High Grade B-Cell Lymphoma Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma	Biological: Anakinra Biological: Axicabtagene Ciloleucel Drug: Cyclophosphamide Drug: Fludarabine Phosphate	Jonsson Comprehensive Cancer Center National Cancer Institute (NCI)	Phase 2
NCT04205409	Nivolumab for Relapsed or Refractory Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies	Recurrent Chronic Lymphocytic Leukemia Recurrent Diffuse Large B-Cell Lymphoma Recurrent Follicular Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3 Follicular Lymphoma Recurrent Grade 3a Follicular Lymphoma Recurrent Marginal Zone Lymphoma Recurrent Non-Hodgkin Lymphoma Recurrent Plasma Cell Myeloma Refractory Chronic Lymphocytic Leukemia Refractory Diffuse Large B-Cell Lymphoma Refractory Follicular Lymphoma Refractory Marginal Zone Lymphoma Refractory Non-Hodgkin Lymphoma Refractory Plasma Cell Myeloma	Biological: Nivolumab	University of Washington National Cancer Institute (NCI) Bristol-Myers Squibb	Phase 2
NCT04196413	GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma (DMG)	Glioma of Spinal Cord Glioma of Brainstem	Drug: GD2 CAR T cells Drug: Fludarabine Drug: Cyclophosphamide	Stanford University CureSearch	Phase 1
NCT04177810	Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer	Metastatic Pancreatic Cancer	Drug: Cemiplimab Drug: Plerixafor	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Genzyme, a Sanofi Company American Association for Cancer Research	Phase 2
NCT04177004	Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant	Allogeneic Hematopoietic Stem Cell Transplant Recipient Hematopoietic and Lymphoid Cell Neoplasms	Procedure: Allogeneic Hematopoietic Stem Cell Transplantation Drug: Cyclophosphamide Drug: Etoposide Radiation: Fractionated Stereotactic Radiation Therapy Drug: Goat Milk Biological: Palifermin Drug: Sirolimus Drug: Tacrolimus	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1
NCT04169737	Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Recurrent Chronic Lymphocytic Leukemia Recurrent Small Lymphocytic Lymphoma Refractory Chronic Lymphocytic Leukemia Refractory Small Lymphocytic Lymphoma	Drug: Acalabrutinib Biological: Obinutuzumab Drug: Venetoclax	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Phase 2

## 해외 바이오의약품 임상 현황 (2020.03.30~2020.04.05)

한국바이오의약품협회, 2020.4.7.  
출처: ClinicalTrials.gov

NCT04160494	D2C7-IT With Atezolizumab for Recurrent Gliomas	Malignant Glioma	Drug: D2C7-IT (6920 ng/mL via convection-enhanced delivery) Drug: Atezolizumab (1200 mg every three weeks)	Darell Bigner Istari Oncology, Inc. National Cancer Institute (NCI) Genentech, Inc. Duke University	Phase 1
NCT04150692	Escalation of Daratumumab Frequency Following Biochemical Progression in Relapsed/Refractory Multiple Myeloma	Multiple Myeloma	Biological: Daratumumab Procedure: Blood for research assessments Procedure: Bone marrow for research assessments	Washington University School of Medicine Janssen, LP	Phase 2
NCT04140162	Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma With Upfront Daratumumab-based Therapy	Multiple Myeloma	Drug: Daratumumab Drug: Lenalidomide Drug: Bortezomib Drug: Dexamethasone	University of Michigan Rogel Cancer Center Janssen Scientific Affairs, LLC	Phase 2
NCT04119830	Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer	Metastatic Colorectal Adenocarcinoma Microsatellite Stable Mismatch Repair Proficient Refractory Colorectal Adenocarcinoma Stage III Colorectal Cancer AJCC v8 Stage IIIA Colorectal Cancer AJCC v8 Stage IIIB Colorectal Cancer AJCC v8 Stage IIIC Colorectal Cancer AJCC v8 Stage IVC Colorectal Cancer AJCC v8 Stage IVA Colorectal Cancer AJCC v8 Stage IVB Colorectal Cancer AJCC v8 Stage IVC Colorectal Cancer AJCC v8 Unresectable Colorectal Carcinoma	Biological: Pembrolizumab Other: Questionnaire Administration Drug: Rintatolimod	Roswell Park Cancer Institute National Cancer Institute (NCI) AIM BioPharma	Phase 2
NCT04117087	Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer	Colorectal Cancer Pancreatic Cancer	Drug: KRAS peptide vaccine Drug: Nivolumab Drug: Ipilimumab	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bristol-Myers Squibb	Phase 1
NCT04111172	Phase 2A Study of Ad5.F35-hGCC-PADRE in Gastrointestinal Malignancies	Pancreatic Ductal Adenocarcinoma Colorectal Adenocarcinoma Gastric Adenocarcinoma Esophageal Adenocarcinoma	Biological: Ad5.F35-hGCC-PADRE	Thomas Jefferson University	Phase 2
NCT04049383	CAR-20/19-T Cells in Pediatric Patients With Relapsed/Refractory B Cell ALL	Acute Lymphoblastic Leukemia, in Relapse Acute Lymphoblastic Leukemia With Failed Remission Acute Lymphoblastic Leukemia Recurrent Acute Lymphoblastic Leukemia Not Having Achieved Remission Acute Lymphoblastic Leukemia, Pediatric Acute Lymphoblastic Leukemia	Biological: CAR-20/19-T cells	Medical College of Wisconsin Children's Hospital and Health System Foundation, Wisconsin	Phase 1
NCT04044534	Intranasal Insulin for Posttraumatic Stress Disorder	PTSD	Drug: Intranasal insulin Drug: Placebo	VA Connecticut Healthcare System	Phase 2
NCT04015700	Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma	Glioblastoma	Biological: Personalized neoantigen DNA vaccine supplied by Genes Therapeutics Device: CELLECTRA@2000 EP Device supplied by Genes Therapeutics Drug: Plasmid encoded IL-12	Washington University School of Medicine	Phase 1
NCT03988283	Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors	Pediatric Recurrent Brain Tumor	Biological: Personalized neoantigen DNA vaccine Device: TDS-IM System Procedure: Peripheral blood draw	Washington University School of Medicine Children's Discovery Institute	Phase 1
NCT03978624	Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer	Bladder Cancer	Drug: Pembrolizumab Drug: Entinostat	UNC Lineberger Comprehensive Cancer Center	Phase 2
NCT03969446	Pembrolizumab and Decitabine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory	Acute Myeloid Leukemia High Risk Myelodysplastic Syndrome Recurrent Acute Myeloid Leukemia Recurrent High Risk Myelodysplastic Syndrome Refractory Acute Myeloid Leukemia Refractory High Risk Myelodysplastic Syndrome Secondary Acute Myeloid Leukemia Therapy-Related Acute Myeloid Leukemia	Drug: Decitabine Biological: Pembrolizumab	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1
NCT03957954	Stem Cell Therapy for Limbal Stem Cell Deficiency	Limbal Stem-cell Deficiency	Biological: cLSC Device: Scleral contact lens (SCL)	University of California, Los Angeles National Eye Institute (NEI) California Institute for Regenerative Medicine (CIRM)	Phase 1
NCT03935594	Use of Autologous Platelet-Rich Plasma to Treat Hypertrophic Burn Scars	Hypertrophic Scar	Biological: PRP Injection Drug: Saline Injection	Vanderbilt University Medical Center	Phase 2
NCT03887741	Plasmapheresis Versus Plasma Infusion From Young APOE3 Homozygotes Into MCI APOE4 Homozygotes to Slow Disease Progression	Mild Cognitive Impairment	Biological: Plasmapheresis Biological: Plasma infusion	Mayo Clinic	Phase 1

## 해외 바이오의약품 임상 현황 (2020.03.30~2020.04.05)

한국바이오의약품협회, 2020.4.7.  
출처: ClinicalTrials.gov

NCT03624062	MER3101: MAS-1 Adjuvanted Antigen-specific Immunotherapeutic for Prevention and Treatment of Type 1 Diabetes	Type 1 Diabetes Mellitus	Drug: MAS-1 adjuvanted Insulin B-chain	University of Colorado, Denver The Leona M. and Harry B. Helmsley Charitable Trust Nova Immunotherapeutics Limited	Phase 1
NCT03527108	Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC	Non Small Cell Lung Cancer	Drug: Nivolumab, ramucirumab Drug: Nivolumab	Fox Chase Cancer Center Bristol-Myers Squibb Eli Lilly and Company	Phase 2
NCT03463239	Bioengineered Penile Tissue Constructs for Irreversibly Damaged Penile Corpora	Urologic Diseases Male Urogenital Diseases Penile Diseases Corpus Callosum Malformation Corpora Cavernosa; Inflammation Trauma Injury	Biological: Autologous tissue engineered corpora	Wake Forest University Health Sciences United States Department of Defense	Phase 1
NCT04305145	Infliximab for Treatment of Ipilimumab Colitis	Melanoma Stage III Melanoma Stage IV Side Effect of Drug Colitis	Drug: Infliximab Drug: Methylprednisolone Drug: Prednisone	Massachusetts General Hospital	Phase 2
NCT04262869	Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer	Lung Non-Small Cell Carcinoma Stage IIIB Lung Cancer AJCC v8 Stage IV Lung Cancer AJCC v8 Stage IVA Lung Cancer AJCC v8 Stage IVB Lung Cancer AJCC v8	Drug: Carboplatin Biological: Durvalumab Drug: Paclitaxel Drug: Pemetrexed	Emory University National Cancer Institute (NCI)	Phase 2
NCT04167540	GDNF Gene Therapy for Parkinson's Disease	Parkinson's Disease	Biological: AAV2-GDNF	Brain Neurotherapy Bio, Inc.	Phase 1
NCT04197596	Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs)	Viral Infection Primary Immune Deficiency Disorder	Biological: BK CTL	New York Medical College Children's Hospital of Philadelphia Medical College of Wisconsin Nationwide Children's Hospital	Phase 1 Phase 2
NCT04315701	A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer	Recurrent Skin Squamous Cell Carcinoma Resectable Skin Squamous Cell Carcinoma Stage I Skin Cancer Stage II Skin Cancer Stage III Skin Cancer	Biological: Cemiplimab Procedure: Resection	University of Southern California National Cancer Institute (NCI)	Phase 2
NCT04213261	A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa	Recessive Dystrophic Epidermolysis Bullosa	Biological: FCX-007 (no generic name is established; see below for FCX-007 description)	Fibrocell Technologies, Inc.	Phase 3
NCT04272645	Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer	Prostate Cancer	Drug: Abemaciclib 200 MG Drug: Atezolizumab 1200 MG in 20 ML Injection Drug: Abemaciclib 150 MG	University of Michigan Rogel Cancer Center	Phase 2
NCT03841565	Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma	Recurrent Plasma Cell Myeloma	Biological: Daratumumab Drug: Dexamethasone Drug: Pomalidomide	Academic and Community Cancer Research United National Cancer Institute (NCI)	Phase 2
NCT04255433	A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes	Type 2 Diabetes Mellitus	Drug: Tirzepatide Drug: Dulaglutide	Eli Lilly and Company	Phase 3
NCT04264806	A Study of Cusatzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)	Myelodysplastic Syndromes Leukemia, Myelomonocytic, Chronic	Drug: Azacitidine Drug: Cusatzumab	Janssen Research & Development, LLC argenx BVBA	Phase 2
NCT04171765	A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis	Non-alcoholic Steatohepatitis	Drug: Placebo Drug: BFKB8488A	Genentech, Inc.	Phase 2
NCT04171531	Sling vs Botox for Mixed Incontinence	Urinary Incontinence, Stress Urinary Incontinence, Urge	Drug: Botox® injection Device: Mid-urethral sling	NICHHD Pelvic Floor Disorders Network Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Women and Infants Hospital of Rhode Island Duke University University of Pennsylvania University of Pittsburgh University of California, San Diego Kaiser Permanente University of Texas Southwestern Medical Center University of Alabama at Birmingham RTI International	Phase 3
NCT04193189	B-Enhancement of HBV Vaccination in Persons Living With HIV (B-E-HiVe): Evaluation of HEPLISAV-B	HIV Infection Hepatitis B	Biological: HEPLISAV-B Biological: ENGERIX-B	National Institute of Allergy and Infectious Diseases (NIAID) Dynavax Technologies Corporation	Phase 3

## 해외 바이오의약품 임상 현황 (2020.03.30~2020.04.05)

한국바이오의약품협회, 2020.4.7.  
출처: ClinicalTrials.gov

### ○ 영국 6건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04075331	Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial	COPD Eosinophilia	Drug: Mepolizumab Drug: Placebo	University of Leicester Leicester Clinical Trials Unit GlaxoSmithKline	Phase 2 Phase 3
NCT04307576	A Treatment Study Protocol for Participants 1-45 Years With Acute Lymphoblastic Leukaemia	Leukemia, Acute Lymphoblastic	Drug: Omitted Doxorubicin Drug: Omitted Vincristine+Dexamethasone pulses Drug: Inotuzumab Ozogamicin+Standard Maintenance Therapy Drug: Imatinib	Mats Heyman The Swedish Research Council The Swedish Childhood Cancer Foundation Pfizer Servier NordForsk Aamu Pediatric Cancer Foundation Gesellschaft für Pädiatrische Onkologie und Hamatologie - Germany Clinical Trial Center North (CTC North GmbH & Co. KG) Belgium Health Care Knowledge Centre Karolinska Institutet Cancer Research UK Fundação Rui Osório de Castro Acreditar - Associação de Pais e Amigos das Crianças com Cancro Grupo Português De Leucemias Pediátricas Karolinska University Hospital	Phase 3
NCT04255433	A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes	Type 2 Diabetes Mellitus	Drug: Tirzepatide Drug: Dulaglutide	Eli Lilly and Company	Phase 3
NCT04264806	A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)	Myelodysplastic Syndromes Leukemia, Myelomonocytic, Chronic	Drug: Azacitidine Drug: Cusatuzumab	Janssen Research & Development, LLC argenx BVBA	Phase 2
NCT04246086	A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide, RO7082859 + Lenalidomide, and RO7082859 + Lenalidomide + Obinutuzumab in Participants With Relapsed or Refractory Follicular Lymphoma	Follicular Lymphoma	Drug: CD20-TCB Drug: Mosunetuzumab Drug: Obinutuzumab Drug: Tocilizumab Drug: Lenalidomide	Hoffmann-La Roche	Phase 1
NCT04245085	ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma	EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC	Drug: Atezolizumab Drug: Bevacizumab Drug: Carboplatin Drug: Paclitaxel Drug: Pemetrexed	European Thoracic Oncology Platform Roche Pharma AG	Phase 2

### ○ 프랑스 8건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04333914	Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 (COVID-19) Infection	SARS-CoV-2 (COVID-19) Infection Advanced or Metastatic Hematological or Solid Tumor	Drug: Chloroquine analog (GNS651) Drug: Nivolumab Drug: Tocilizumab Other: Standard of care	Centre Leon Berard	Phase 2
NCT04333368	Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS	Severe Acute Respiratory Syndrome Coronavirus 2 Severe Acute Respiratory Distress Syndrome	Biological: Umbilical cord Wharton's jelly-derived human Other: NaCl 0.9%	Assistance Publique - Hôpitaux de Paris	Phase 1 Phase 2
NCT03970954	Low-dose Interleukin-2 in Women With Unexplained Miscarriages	Recurrent Miscarriage	Drug: low-dose IL-2	Assistance Publique - Hôpitaux de Paris Ilto Pharma	Phase 1 Phase 2
NCT04263051	Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer	Advanced Non-small Cell Lung Cancer	Drug: UCPVax + Nivolumab Drug: standard chemotherapy	Centre Hospitalier Universitaire de Besançon Bristol-Myers Squibb	Phase 2
NCT04246086	A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide, RO7082859 + Lenalidomide, and RO7082859 + Lenalidomide + Obinutuzumab in Participants With Relapsed or Refractory Follicular Lymphoma	Follicular Lymphoma	Drug: CD20-TCB Drug: Mosunetuzumab Drug: Obinutuzumab Drug: Tocilizumab Drug: Lenalidomide	Hoffmann-La Roche	Phase 1
NCT04255433	A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes	Type 2 Diabetes Mellitus	Drug: Tirzepatide Drug: Dulaglutide	Eli Lilly and Company	Phase 3
NCT04264806	A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)	Myelodysplastic Syndromes Leukemia, Myelomonocytic, Chronic	Drug: Azacitidine Drug: Cusatuzumab	Janssen Research & Development, LLC argenx BVBA	Phase 2
NCT04171765	A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis	Non-alcoholic Steatohepatitis	Drug: Placebo Drug: BFKB8488A	Genentech, Inc.	Phase 2

## 해외 바이오의약품 임상 현황 (2020.03.30~2020.04.05)

한국바이오의약품협회, 2020.4.7.  
출처: ClinicalTrials.gov

### ○ 독일 6건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04073147	Venetoclax and Obinutuzumab for Relapsed Primary CNS Lymphoma	Primary CNS Lymphoma	Drug: Venetoclax Drug: Obinutuzumab	Klinikum Stuttgart University Hospital Freiburg	Phase 1
NCT04195373	A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract	Gastrointestinal Cancer	Biological: TMV-018 + 5-FC Biological: TMV-018 + anti-PD-1 Biological: TMV-018 + 5-FC + anti-PD-1	Themis Bioscience GmbH Assign Data Management and Biostatistics GmbH SSS International Clinical Research GmbH	Phase 1 Phase 2
NCT04255433	A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes	Type 2 Diabetes Mellitus	Drug: Tirzepatide Drug: Dulaglutide	Eli Lilly and Company	Phase 3
NCT04307576	A Treatment Study Protocol for Participants 1-45 Years With Acute Lymphoblastic Leukaemia	Leukemia, Acute Lymphoblastic	Drug: Omitted Doxorubicin Drug: Omitted Vincristine+Dexamethasone pulses Drug: Inotuzumab Ozogamicin+Standard Maintenance Therapy Drug: Imatinib	Mats Heyman The Swedish Research Council The Swedish Childhood Cancer Foundation Pfizer Servier NordForsk Aamu Pediatric Cancer Foundation Gesellschaft für Pädiatrische Onkologie und Hamatologie - Germany Clinical Trial Center North (CTC North GmbH & Co. KG) Belgium Health Care Knowledge Centre Karolinska Institutet Cancer Research UK Fundação Rui Osório de Castro Acreditar - Associação de Pais e Amigos das Crianças com Cancro Grupo Português De Leucemias Pediátricas Karolinska University Hospital	Phase 3
NCT04264806	A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)	Myelodysplastic Syndromes Leukemia, Myelomonocytic, Chronic	Drug: Azacitidine Drug: Cusatuzumab	Janssen Research & Development, LLC argenx BVBA	Phase 2
NCT04245085	ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma	EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC	Drug: Atezolizumab Drug: Bevacizumab Drug: Carboplatin Drug: Paclitaxel Drug: Pemetrexed	European Thoracic Oncology Platform Roche Pharma AG	Phase 2

### ○ 일본 3건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04241549	A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment	Leukemia, Myeloid, Acute	Drug: Cusatuzumab Drug: Azacitidine	Janssen Pharmaceutical K.K. argenx BVBA	Phase 1
NCT04255433	A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes	Type 2 Diabetes Mellitus	Drug: Tirzepatide Drug: Dulaglutide	Eli Lilly and Company	Phase 3
NCT04264806	A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)	Myelodysplastic Syndromes Leukemia, Myelomonocytic, Chronic	Drug: Azacitidine Drug: Cusatuzumab	Janssen Research & Development, LLC argenx BVBA	Phase 2

# 해외 바이오의약품 임상 현황 (2020.03.30~2020.04.05)

한국바이오의약품협회, 2020.4.7.  
출처: ClinicalTrials.gov

## ○ 중국 19건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04314011	Clinical Study of Umbilical Cord Mesenchymal Stem Cells Infusion for Aging Frailty	Aging Frailty	Biological: Human umbilical cord mesenchymal stem cells ( HUC-MSCs )  Biological: Placebo	Shanghai East Hospital Xuanwu Hospital, Beijing	Phase 1 Phase 2
NCT04233892	Clinical Study of in Situ Regeneration of Endometrium	Infertility, Female, of Uterine Origin Endometrial Fibrosis	Drug: CBD-bFGF Drug: Collagen/BMMNCs Drug: Estrogen	Yali Hu Chinese Academy of Sciences The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	Phase 1 Phase 2
NCT04331093	Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma	Acral Melanoma	Drug: SHR-1210+Apatinib	Di Wu First Hospital of Jilin University	Phase 2
NCT04328831	Safety and Efficacy of IBI322 in Chinese Subjects With Advanced Malignant Tumors	Advanced Malignancies	Biological: IBI322	Innovent Biologics (Suzhou) Co. Ltd.	Phase 1
NCT04326296	The Safety and Tolerability of PD-L1 Monoclonal Antibody Plus Lenalidomide in The Treatment of Colorectal Cancer	Colorectal Neoplasms	Drug: PD-L1 Monoclonal Antibody Combined With Lenalidomide	Lining Henan Cancer Hospital	Phase 1
NCT04310943	Efficacy and Safety of Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in Lung Adenocarcinoma	Lung Adenocarcinoma Stage IV	Drug: Tislelizumab	Zhou Chengzhi Guangzhou Institute of Respiratory Disease	Phase 2
NCT04304248	Neoadjuvant Toripalimab Plus Platinum-based Doublet for Stage III Non-small Cell Lung Cancer	Non Small Cell Lung Cancer	Drug: Albumin-bound paclitaxel, Carboplatin, Toripalimab	Hao Long Sun Yat-sen University	Phase 2
NCT04302103	A Study of TACI ( Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor ) - Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis	Systemic Myasthenia Gravis	Biological: RC18 160mg Biological: RC18 240 mg	RemeGen	Phase 2
NCT04298060	DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)	Influenza Infection SAD-RV Infection and COVID-19	Drug: DAS181 Drug: Placebo	Ansun Biopharma, Inc.	Phase 2
NCT04289285	Safety and Efficacy of IBI306 in Chinese Subjects With Non-familial Hypercholesterolemia	Hypercholesterolemia	Drug: IBI306 450mg SC Q4W Drug: Placebo SC Q4W Drug: IBI306 600mg SC Q6W Other: Placebo SC Q6W Other: Placebo SC Q8W	Innovent Biologics (Suzhou) Co. Ltd.	Phase 3
NCT04278859	A Phase I Clinical Study of JS004 in Subjects With Advanced Solid Malignancies of China	Advanced Solid Tumor	Biological: Drug: JS004, Recombinant humanized IgG4κ monoclonal antibody specific to BTLA for injection Intravenous infusion	Shanghai Junshi Bioscience Co., Ltd.	Phase 1
NCT04221971	NK Cell Infusion for Patients With Acute Myeloid Leukemia	Acute Myeloid Leukemia	Drug: chemotherapy combined with NK cells infusion	Peking University People's Hospital The University of Science and Technology of China	Phase 1
NCT04100772	Phase I Clinical Trial of One Vaccine	Pneumococcal Infections Streptococcal Infections	Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine ( CRM197,TT )  Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine	CanSino Biologics Inc. Henan Center for Disease Control and Prevention	Phase 1
NCT03524261	Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Breast Cancer	Advanced Breast Cancer	Biological: Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Breast Cancer Procedure: cryotherapy	Fuda Cancer Hospital, Guangzhou Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.	Phase 2
NCT04317248	"Cocktail" Therapy for Hepatitis B Related Hepatocellular Carcinoma	Hepatocellular Carcinoma	Drug: Cyclophosphamide Biological: Multiple Signals loaded Dendritic Cells Vaccine	Yuehua Huang Sun Yat-sen University Nanfang Hospital of Southern Medical University Third Affiliated Hospital, Sun Yat-Sen University	Phase 2
NCT04329429	A Study of RC48 in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer.	Biliary Tract Cancer	Drug: RC48-ADC	RemeGen	Phase 2
NCT04325763	A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)	Stage III Non-small-cell Lung Cancer	Drug: TQB2450 Drug: Anlotinib Drug: TQB2450(blank) Drug: Anlotinib(blank)	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Phase 3
NCT04285229	A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial Spondyloarthritis	Spondyloarthritis	Drug: Ixekizumab Drug: Placebo	Eli Lilly and Company	Phase 3
NCT04255433	A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes	Type 2 Diabetes Mellitus	Drug: Tirzepatide Drug: Dulaglutide	Eli Lilly and Company	Phase 3